292 related articles for article (PubMed ID: 21827695)
1. Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer.
Serrano D; Bleau AM; Fernandez-Garcia I; Fernandez-Marcelo T; Iniesta P; Ortiz-de-Solorzano C; Calvo A
Mol Cancer; 2011 Aug; 10():96. PubMed ID: 21827695
[TBL] [Abstract][Full Text] [Related]
2. Combination treatment with flavonoid morin and telomerase inhibitor MST‑312 reduces cancer stem cell traits by targeting STAT3 and telomerase.
Chung SS; Oliva B; Dwabe S; Vadgama JV
Int J Oncol; 2016 Aug; 49(2):487-98. PubMed ID: 27279256
[TBL] [Abstract][Full Text] [Related]
3. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
[TBL] [Abstract][Full Text] [Related]
4. Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells.
Di Martile M; Desideri M; De Luca T; Gabellini C; Buglioni S; Eramo A; Sette G; Milella M; Rotili D; Mai A; Carradori S; Secci D; De Maria R; Del Bufalo D; Trisciuoglio D
Oncotarget; 2016 Mar; 7(10):11332-48. PubMed ID: 26870991
[TBL] [Abstract][Full Text] [Related]
5. Garcinol inhibits cancer stem cell-like phenotype via suppression of the Wnt/β-catenin/STAT3 axis signalling pathway in human non-small cell lung carcinomas.
Huang WC; Kuo KT; Adebayo BO; Wang CH; Chen YJ; Jin K; Tsai TH; Yeh CT
J Nutr Biochem; 2018 Apr; 54():140-150. PubMed ID: 29414668
[TBL] [Abstract][Full Text] [Related]
6. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
7. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling.
Sullivan JP; Spinola M; Dodge M; Raso MG; Behrens C; Gao B; Schuster K; Shao C; Larsen JE; Sullivan LA; Honorio S; Xie Y; Scaglioni PP; DiMaio JM; Gazdar AF; Shay JW; Wistuba II; Minna JD
Cancer Res; 2010 Dec; 70(23):9937-48. PubMed ID: 21118965
[TBL] [Abstract][Full Text] [Related]
8. Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells.
Liu X; Wang L; Cui W; Yuan X; Lin L; Cao Q; Wang N; Li Y; Guo W; Zhang X; Wu C; Yang J
Oncotarget; 2016 Sep; 7(36):58516-58530. PubMed ID: 27542268
[TBL] [Abstract][Full Text] [Related]
9. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
10. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer.
Jiang F; Qiu Q; Khanna A; Todd NW; Deepak J; Xing L; Wang H; Liu Z; Su Y; Stass SA; Katz RL
Mol Cancer Res; 2009 Mar; 7(3):330-8. PubMed ID: 19276181
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Roles of Curcumin in Sensitising the Cisplatin Effect on a Cancer Stem Cell-Like Population Derived from Non-Small Cell Lung Cancer Cell Lines.
Abdul Satar N; Ismail MN; Yahaya BH
Molecules; 2021 Feb; 26(4):. PubMed ID: 33670440
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist.
Prud'homme GJ; Glinka Y; Toulina A; Ace O; Subramaniam V; Jothy S
PLoS One; 2010 Nov; 5(11):e13831. PubMed ID: 21072210
[TBL] [Abstract][Full Text] [Related]
14. TMPRSS4 induces cancer stem cell-like properties in lung cancer cells and correlates with ALDH expression in NSCLC patients.
de Aberasturi AL; Redrado M; Villalba M; Larzabal L; Pajares MJ; Garcia J; Evans SR; Garcia-Ros D; Bodegas ME; Lopez L; Montuenga L; Calvo A
Cancer Lett; 2016 Jan; 370(2):165-76. PubMed ID: 26546046
[TBL] [Abstract][Full Text] [Related]
15. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
Koziel JE; Herbert BS
Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
[TBL] [Abstract][Full Text] [Related]
16. Lung cancer tumorigenicity and drug resistance are maintained through ALDH(hi)CD44(hi) tumor initiating cells.
Liu J; Xiao Z; Wong SK; Tin VP; Ho KY; Wang J; Sham MH; Wong MP
Oncotarget; 2013 Oct; 4(10):1698-1711. PubMed ID: 24091605
[TBL] [Abstract][Full Text] [Related]
17. Essential role of aldehyde dehydrogenase 1A3 for the maintenance of non-small cell lung cancer stem cells is associated with the STAT3 pathway.
Shao C; Sullivan JP; Girard L; Augustyn A; Yenerall P; Rodriguez-Canales J; Liu H; Behrens C; Shay JW; Wistuba II; Minna JD
Clin Cancer Res; 2014 Aug; 20(15):4154-66. PubMed ID: 24907115
[TBL] [Abstract][Full Text] [Related]
18. BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation.
Wang L; Park P; La Marca F; Than KD; Lin CY
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1013-24. PubMed ID: 25431339
[TBL] [Abstract][Full Text] [Related]
19. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
Navas T; Pfister TD; Colantonio S; Aziz A; Dieckman L; Saul RG; Kaczmarczyk J; Borgel S; Alcoser SY; Hollingshead MG; Lee YH; Bottaro DP; Hiltke T; Whiteley G; Takebe N; Kinders RJ; Parchment RE; Tomaszewski JE; Doroshow JH
PLoS One; 2018; 13(6):e0199361. PubMed ID: 29928062
[TBL] [Abstract][Full Text] [Related]
20. A novel reporter construct for screening small molecule inhibitors that specifically target self-renewing cancer cells.
Shanmugam G; Mohan A; Kumari K; Louis JM; Soumya Krishnan U; Balagopal PG; George NA; Sebastian P; Maliekal TT
Exp Cell Res; 2019 Oct; 383(2):111551. PubMed ID: 31401066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
